Respiratory failure affects 17/1000 patients in the US and is the most common cause of 30-day postoperative mortality. Unplanned ICU admissions may have respiratory indication in 17-47% of cases. Prediction of hypoxia via STOP-BANG (Snoring, Tiredness, observed apnea, blood Pressure, Body mass index, Age, Neck circumference and Gender) score is not reliable. Hypotension and hypoxemia on the general care floor (GCF) is Common, profound, prolong and accounts for 49% of cardiac arrest on GCF. Respiratory monitoring in more challenging environments such as those faced by military personnel have no practical technological tools today. The Linshom Respiratory Monitor an FDA 510(k) cleared device improves patient safety by providing continuous, uninterrupted, critical respiratory information through innovative monitoring technology. Linshom is safe, reliable, noninvasive, simple to apply to the patient and answers a critical unmet medical need. Linshom is patented in the U.S, and internationally. Linshom delivers respiratory rate and relative tidal volume information accurately and reliably. The signal is not affected by supplemental oxygen, nor does it suffer from motion artifact. Linshom has a small and light footprint with low energy requirements. The Linshom thermal sensor is regulated by a thermoelectric cooler utilizing a patented control loop process. It is non-invasive, portable, not corrupted by motion artifacts and easily mounts to mask or nasal cannula. Linshom delivers the respiratory information without complicated hardware and firmware processing and has passed 60601 EMC and safety testing as well as receiving FDA 510(k) clearance.
